Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended) A compound of formula I

wherein

X is $=CR^0$ - or =N-:

each of R⁰, R¹, R², R³ and R⁴ independently is hydrogen; hydroxy; C₁-C₈alkyl; C₂-C₈alkenyl; C₃-C₈cycloalkyl; C₃-C₈cycloalkyl-C₁-C₈alkyl; hydroxyC₁-C₈alkyl; C₁-C₈alkoxyC₁-C₈alkyl; hydroxyC₁-C₈alkoxyC₁-C₈alkyl; arylC₁-C₈alkyl which optionally may be substituted on the ring by hydroxy, C₁-C₈alkoxy, carboxy or C₁-C₈alkoxycarbonyl;

or R³ and R⁴ form together with the nitrogen and carbon atoms to which they are attached a 5 to 10 membered heterocyclic ring and having 1, 2 or 3 heteroatoms selected from N, O and S;

or each of R¹, R² and R³, independently, is halogen; halo-C₁-C₈alkyl; C₁-C₈alkoxy; halo-C₁-C₈alkoxy; hydroxyC₁-C₈alkoxy; C₁-C₈alkoxyC₁-C₈alkoxy; aryl; arylC₁-C₈alkoxy; heteroaryl; heteroaryl-C₁-C₄alkyl; 5 to 10 membered heterocyclic ring; nitro; carboxy;

 $C_2\text{-}C_8 alkoxy carbonyl; \ C_2\text{-}C_8 alkyl carbonyl; \ -N(C_1\text{-}C_8 alkyl)C(O) \ C_1\text{-}C_8 alkyl; \ -N(R^{10})R^{11};$

 $-CON(R^{10})R^{11}; -SO_2N(R^{10})R^{11}; \text{ or } -C_1-C_4-\text{alkylene-SO}_2N(R^{10})R^{11}; \text{ wherein each of } R^{10} \text{ and } R^{11} \text{ independently is hydrogen; hydroxy; } C_1-C_8\text{alkyl}; C_2-C_8\text{alkenyl}; C_3-C_8\text{cycloalkyl}; \\$

 C_3 - C_8 cycloalkyl- C_1 - C_8 alkyl; C_1 - C_8 alkoxy C_1 - C_8 alkyl; hydroxy C_1 - C_8 alkyl; hydroxy C_1 - C_8 alkyl; (C_1 - C_8 alkyl)-carbonyl; aryl C_1 - C_8 alkyl which optionally may be substituted on the ring by hydroxy, C_1 - C_8 alkoxy, carboxy or C_2 - C_8 alkoxycarbonyl; or 5 to 10 membered heterocyclic ring;

or R¹ and R² form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl group having one or two heteroatoms selected from N, O and S; or

each of R⁵ and R⁶ independently is hydrogen; halogen; cyano; C₁-C₈alkyl; halo-C₁-C₈alkyl;

C₂-C₈alkenyl; C₂-C₈alkynyl; C₃-C₈cycloalkyl; C₃-C₈cycloalkylC₁-C₈alkyl; C₅-C₁₀arylC₁-C₈alkyl;

R⁶ is hydrogen;

each of R⁷, R⁸ and R⁹ is independently hydrogen; hydroxy; C₁-C₈alkyl; C₂-C₈alkenyl;

halo- C_1 - C_8 alkyl; C_1 - C_8 alkoxy; C_3 - C_8 cycloalkyl; C_3 - C_8 cycloalkyl C_1 - C_8 alkyl; aryl C_1 - C_8 alkyl;

-Y-R¹² wherein Y is a direct bond or O and R¹² is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring having 1, 2 or 3 heteroatoms selected from N, O and S; carboxy; (C₁-C₈alkoxy)-carbonyl; -N(C₁₋₈alkyl)-CO-NR¹⁰R¹¹; -CONR¹⁰R¹¹; -N(R¹⁰)(R¹¹);

—SO₂N(R¹⁰)R¹¹; R⁷ and R⁸ or R⁸ and R⁹, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl having 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring;

provided that one of R^1 , R^2 or R^3 is -CON(R^{10}) R^{11} or-SO₂N(R^{10}) R^{11} ;

in free form or salt form;

wherein

aryl represents phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl,

heteroaryl is a 5 or 6 membered aromatic heterocyclic ring, optionally condensed to 1 or 2 benzene rings and/or to a further heterocyclic ring, and

wherein a heterocyclic ring is a 5 or 6 membered heterocyclic ring being saturated or unsaturated and optionally condensed to 1 or 2 benzene rings and/or to a further heterocyclic ring.

2. (Original) A process for the production of a compound of formula I according to claim 1, comprising the steps of reacting a compound of formula II

wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and X are as defined in claim 1, and Y is a leaving group; with a compound of formula III

$$R^7$$
 R^8
 R^9
(III)

wherein R7, R8 and R9 are as defined in claim 1;

and recovering the resulting compound of formula I in free form or in salt form, and, where required, converting the compound of formula I obtained in free form into the desired salt form, or vice versa.

- 3. (Canceled)
- 4. (Original) A pharmaceutical composition comprising a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers or diluents therefor.
- 5. (Canceled)
- 6. (Canceled)
- 7. (Cancelled)
- 8. (Currently Amended) A method for treating acute or chronic rejection of organ or tissue, atheriosclerosis, vascular occlusion, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS disease, breast cancer, infectious disease, inflammatory disease, or autoimmune disease, in a subject in need of such treatment, which comprises comprising: administering to a such subject in need thereof, a therapeutically effective amount of a the compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.
- 9. (Cancelled)